

November 13, 2017  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## **Initiation of an Arbitration against The Medicines Company**

TOKYO, Japan, November 10, 2017 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio"), initiated an arbitration against The Medicines Company (Headquarters: Parsippany, New Jersey, "MDCO") on October 11, 2017, under the rules of International Chamber of Commerce, seeking damages arising out of MDCO's repudiation of the license agreement ("License Agreement") entered into between SymBio and MDCO on October 5, 2015 for the exclusive rights to develop and commercialize the patient-controlled pain management drug "IONSYS" or "SyB P-1501" in Japan. MDCO's alleged breaches relate to its decision to discontinue and withdraw IONSYS® from the United States and European markets and failure to provide adequate assurances of its performance under the License Agreement. SymBio seeks damages of US\$ 82 million (approximately JPY 9 billion).

In contravention of the terms of the License Agreement, MDCO disclosed the existence of the arbitration in its Form 10-Q filing on November 9, 2017. MDCO's Form 10-Q refers to counterclaims against SymBio. SymBio has not received and does not believe that MDCO has any viable counterclaims, and will vigorously defend against any that are asserted.

MDCO's Form 10-Q also states that the License Agreement has terminated. SymBio disagrees with this statement and believes that the License Agreement has not yet terminated. SymBio is assessing its position, including in respect of the temporary suspension of the domestic phase 3 clinical trial of "SyB P-1501". SymBio will make a timely disclosure once it has reached a decision about the trial and when the License Agreement has terminated.

**[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125

**About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016 the SymBio incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The SymBio's underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.